$ALT News

Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10

Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near

Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

Altimmune to Participate in Upcoming Investor Conferences

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

Altimmune Announces New Data From Phase 2b Trial Of Pemvidutide Showing Improvements Across Multiple Non-Invasive Tests Of Metabolic Dysfunction-Associated Steatoheaptitis Activity And Fibrosis.

HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20

Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil

Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11

Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript

Altimmune Inc (ALT) Q1 2026 Earnings Call Highlights: Strong Cash Position and Strategic ...

Altimmune (ALT) Q1 2026 Earnings Transcript

Altimmune Q1 Earnings Call Highlights

Altimmune Q1 2026 Earnings Call: Complete Transcript

Altimmune shares climb after first-quarter loss beats expectations (ALT)

Altimmune Announces First Quarter 2026 Financial Results and Business Update

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

Altimmune Q1 2026 Earnings Call: Complete Transcript